Myostatin: a potential therapeutic target for metabolic syndrome

Abstract

Metabolic syndrome is a complex metabolic disorder, its main clinical manifestations are obesity, hyperglycemia, hypertension and hyperlipidemia. Although metabolic syndrome has been the focus of research in recent decades, it has been proposed that the occurrence and development of metabolic syndrome is related to pathophysiological processes such as insulin resistance, adipose tissue dysfunction and chronic inflammation, but there is still a lack of favorable clinical prevention and treatment measures for metabolic syndrome. Multiple studies have shown that myostatin (MSTN), a member of the TGF-β family, is involved in the development and development of obesity, hyperlipidemia, diabetes, and hypertension (clinical manifestations of metabolic syndrome), and thus may be a potential therapeutic target for metabolic syndrome. In this review, we describe the transcriptional regulation and receptor binding pathway of MSTN, then introduce the role of MSTN in regulating mitochondrial function and autophagy, review the research progress of MSTN in metabolic syndrome. Finally summarize some MSTN inhibitors under clinical trial and proposed the use of MSTN inhibitor as a potential target for the treatment of metabolic syndrome.

Unveiling the Potential of Nelumbo nucifera-Derived Liensinine to Target The Myostatin Protein and to Counteract Muscle Atrophy

“…LIE can bind to the residues PRO-76 and MET-79 in the active pocket of MSTN, forming steric hindrance that affects the interaction between MSTN and ActRIIB. Additionally, LIE inhibits MSTN protein expression in vitro and in vivo , collectively leading to the suppression of downstream phosphorylation of the drosophila mothers against decapentaplegic protein (Smad) 2/3 complex and dephosphorylation of the forkhead box O (FOXO), further inhibiting the expression of the muscle atrophy-related proteins MuRF-1 and Atrogin-1 …”